Compare RUN & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RUN | ADMA |
|---|---|---|
| Founded | 2007 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 4.1B |
| IPO Year | 2015 | N/A |
| Metric | RUN | ADMA |
|---|---|---|
| Price | $17.91 | $19.86 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 18 | 2 |
| Target Price | $20.63 | ★ $28.50 |
| AVG Volume (30 Days) | ★ 7.1M | 2.9M |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 205.35 |
| EPS | N/A | ★ 0.86 |
| Revenue | ★ $2,316,656,000.00 | $488,559,000.00 |
| Revenue This Year | $18.66 | $22.19 |
| Revenue Next Year | $6.33 | $24.33 |
| P/E Ratio | ★ N/A | $23.11 |
| Revenue Growth | 13.79 | ★ 27.63 |
| 52 Week Low | $5.38 | $13.50 |
| 52 Week High | $22.44 | $25.67 |
| Indicator | RUN | ADMA |
|---|---|---|
| Relative Strength Index (RSI) | 46.24 | 66.02 |
| Support Level | $17.47 | $19.13 |
| Resistance Level | $18.91 | $20.22 |
| Average True Range (ATR) | 1.02 | 0.73 |
| MACD | -0.01 | 0.05 |
| Stochastic Oscillator | 20.10 | 79.44 |
Sunrun is engaged in the design, development, installation, sale, ownership, and maintenance of residential solar energy systems in the United States. The company acquires customers directly and through relationships with various solar and strategic partners. The solar systems are constructed by Sunrun or by Sunrun's partners and are owned by the company. Sunrun's customers typically enter into 20- to 25-year agreements to utilize its solar energy system. The company also sells solar energy systems and products, such as panels and racking, and solar leads generated to customers.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.